{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:33:12Z","timestamp":1790044392449,"version":"4.0.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Beijing Hope Run Special Fund of Cancer Foundation of the People\u2019s Republic of China","award":["LC2019L04"],"award-info":[{"award-number":["LC2019L04"]}]},{"name":"National Key Research and Development Program of China","award":["2022YFC2409902"],"award-info":[{"award-number":["2022YFC2409902"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06118-9","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T10:39:28Z","timestamp":1740739168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Pan-cancer analysis to character the clinicopathological and genomic features of KRAS-mutated patients in China"],"prefix":"10.1007","volume":"151","author":[{"given":"Liyuan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanshuang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"6118_CR1","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.21037\/jtd.2020.04.18","volume":"12","author":"I Amanam","year":"2020","unstructured":"Amanam I, Mambetsariev I, Gupta R, Achuthan S, Wang Y, Pharaon R, Massarelli E, Koczywas M, Reckamp K, Salgia R (2020) Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival. J Thorac Dis 12:5086\u20135095. https:\/\/doi.org\/10.21037\/jtd.2020.04.18","journal-title":"J Thorac Dis"},{"key":"6118_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cells7020014","author":"G Cazzanelli","year":"2018","unstructured":"Cazzanelli G, Pereira FA-O, Alves SA-O, Francisco R, Azevedo L, Dias Carvalho P, Almeida A, C\u00f4rte-Real M, Oliveira MJ, Lucas C, Sousa MA-O, Preto A (2018) The yeast Saccharomyces cerevisiae as a model for understanding RAS proteins and their role in human tumorigenesis. Cells. https:\/\/doi.org\/10.3390\/cells7020014","journal-title":"Cells"},{"key":"6118_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, Huang F, He Y et al (2017) Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9:34. https:\/\/doi.org\/10.1186\/s13073-017-0424-2","journal-title":"Genome Med."},{"key":"6118_CR4","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","volume":"23","author":"LA Diaz Jr","year":"2022","unstructured":"Diaz LA Jr, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, de la Fourchardiere C, Rivera F et al (2022) Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol 23:659","journal-title":"Lancet Oncol"},{"key":"6118_CR5","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","volume":"23","author":"ZY Dong","year":"2017","unstructured":"Dong ZY, Zhong WZ, Zhang XC, Su J, Xie Z, Liu SY, Tu HY, Chen HJ, Sun YL, Zhou Q, Yang JJ, Yang XN et al (2017) Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res 23:3012\u20133024. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2554","journal-title":"Clin Cancer Res"},{"key":"6118_CR6","doi-asserted-by":"publisher","first-page":"xi64","DOI":"10.1093\/annonc\/mdz453.002","volume":"30","author":"S Gadgeel","year":"2019","unstructured":"Gadgeel S, Rodriguez-Abreu D, Felip E, Esteban E, Speranza G, Reck M, Hui R, Boyer M, Garon EB, Horinouchi H, Cristescu R, Aurora-Garg D et al (2019) KRAS mutational status and efficacy in KEYNOTE-189: pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC. Ann Oncol 30:xi64\u2013xi65. https:\/\/doi.org\/10.1093\/annonc\/mdz453.002","journal-title":"Ann Oncol"},{"key":"6118_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 6:1. https:\/\/doi.org\/10.1126\/scisignal.2004088","journal-title":"Sci Signal."},{"key":"6118_CR8","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, Laguer J, Medwid J, Vanderpool D, Lifset E, Trinh D, Hoffman N et al (2022) Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor. Nat Med 28:2171\u20132182. https:\/\/doi.org\/10.1038\/s41591-022-02007-7","journal-title":"Nat Med"},{"key":"6118_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","volume":"62","author":"KM Hargadon","year":"2018","unstructured":"Hargadon KM, Johnson CE, Williams CJ (2018) Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol 62:29\u201339. https:\/\/doi.org\/10.1016\/j.intimp.2018.06.001","journal-title":"Int Immunopharmacol"},{"key":"6118_CR10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02446","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, Garon EB, Kim DW, Cho BC, Perez-Gracia JL, Han JY, Arvis CD, Majem M, Forster MD, Monnet I, Novello S, Szalai Z et al (2020) Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1-positive, advanced non-small-cell lung cancer in the KEYNOTE-010 study. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.19.02446","journal-title":"J Clin Oncol"},{"key":"6118_CR11","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1158\/1541-7786.MCR-15-0203","volume":"13","author":"JC Hunter","year":"2015","unstructured":"Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD (2015) Biochemical and structural analysis of common cancer-associated KRAS mutations. Mol Cancer Res 13:1325\u20131335. https:\/\/doi.org\/10.1158\/1541-7786.MCR-15-0203","journal-title":"Mol Cancer Res"},{"key":"6118_CR12","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.21037\/tlcr-24-165","volume":"13","author":"J Jiang","year":"2024","unstructured":"Jiang J, Berry MF, Lui NS, Liou DZ, Trope WL, Backhus LM, Shrager JB (2024) Clinical impact of EGFR and KRAS mutations in surgically treated unifocal and multifocal lung adenocarcinoma. Transl Lung Cancer Res. 13:1222\u20131231. https:\/\/doi.org\/10.21037\/tlcr-24-165","journal-title":"Transl Lung Cancer Res."},{"key":"6118_CR13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","volume":"13","author":"SB Kemp","year":"2023","unstructured":"Kemp SB, Cheng N, Markosyan N, Sor R, Kim IK, Hallin J, Shoush J, Quinones L, Brown NV, Bassett JB, Joshi N, Yuan S et al (2023) Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer. Cancer Discov 13:298\u2013311. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-1066","journal-title":"Cancer Discov"},{"key":"6118_CR14","doi-asserted-by":"publisher","first-page":"48248","DOI":"10.18632\/oncotarget.17594","volume":"8","author":"JH Kim","year":"2017","unstructured":"Kim JH, Kim HS, Kim BJ (2017) Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: a meta-analysis and review. Oncotarget 8:48248\u201348252. https:\/\/doi.org\/10.18632\/oncotarget.17594","journal-title":"Oncotarget"},{"key":"6118_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031309","author":"AM Kulkarni","year":"2022","unstructured":"Kulkarni AM, Kumar VA-O, Parate SA-O, Lee G, Yoon S, Lee KW (2022) Identification of new KRAS G12D inhibitors through computer-aided drug discovery methods. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23031309","journal-title":"Int J Mol Sci"},{"key":"6118_CR16","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, Watkins TB, Shafi S et al (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351:1463\u20131469. https:\/\/doi.org\/10.1126\/science.aaf1490","journal-title":"Science"},{"key":"6118_CR17","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","volume":"28","author":"EC Nakajima","year":"2022","unstructured":"Nakajima EC, Drezner N, Li X, Mishra-Kalyani PS, Liu Y, Zhao H, Bi Y, Liu J, Rahman A, Wearne E, Ojofeitimi I, Hotaki LT et al (2022) FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC. Clin Cancer Res 28:1482\u20131486. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3074","journal-title":"Clin Cancer Res"},{"key":"6118_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N et al (2015) Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. https:\/\/doi.org\/10.1126\/science.aaa1348","journal-title":"Science"},{"key":"6118_CR19","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccr.2014.02.017","volume":"25","author":"AG Stephen","year":"2014","unstructured":"Stephen AG, Esposito D, Bagni RK, McCormick F (2014) Dragging ras back in the ring. Cancer Cell 25:272\u2013281. https:\/\/doi.org\/10.1016\/j.ccr.2014.02.017","journal-title":"Cancer Cell"},{"key":"6118_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166626","author":"H Sumimoto","year":"2016","unstructured":"Sumimoto H, Takano A, Teramoto K, Daigo Y (2016) RAS-mitogen-activated protein kinase signal is required for enhanced PD-L1 expression in human lung cancers. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0166626","journal-title":"PLoS ONE"},{"key":"6118_CR21","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jmoldx.2019.06.011","volume":"21","author":"SE Trabucco","year":"2019","unstructured":"Trabucco SE, Gowen K, Maund SL, Sanford E, Fabrizio DA, Hall MJ, Yakirevich E, Gregg JP, Stephens PJ, Frampton GM, Hegde PS, Miller VA et al (2019) A novel next-generation sequencing approach to detecting microsatellite instability and pan-tumor characterization of 1000 microsatellite instability-high cases in 67,000 patient samples. J Mol Diagn 21:1053\u20131066. https:\/\/doi.org\/10.1016\/j.jmoldx.2019.06.011","journal-title":"J Mol Diagn"},{"key":"6118_CR22","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/cas.15650","volume":"114","author":"TA-O Yoshino","year":"2023","unstructured":"Yoshino TA-O, Andre T, Kim TW, Yong WP, Shiu KK, Jensen BV, Jensen LH, Punt CJA, Smith D, Garcia-Carbonero R, Alcaide-Garcia J, Gibbs P et al (2023) Pembrolizumab in Asian patients with microsatellite-instability-high\/mismatch-repair-deficient colorectal cancer. Cancer Sci 114:1026","journal-title":"Cancer Sci"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06118-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06118-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06118-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T17:36:02Z","timestamp":1741800962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06118-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["6118"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06118-9","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The NGS data included in this study have been subjected to a rigorous review process by the CHCAMS Ethics Committee, and ethical approval has been granted (NCC2694). The study was conducted in accordance with the ethical principles set forth in the Declaration of Helsinki for research involving human subjects. Prior to participation, all subjects were required to sign an informed consent form, which provided detailed information about the purpose of the experiment, the methods to be employed, the potential risks, the expected benefits, and the subjects' rights.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"94"}}